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The management of symptomatic chronic mesen-
teric occlusive disease (SCMOD) represents a diffi-
cult challenge to the vascular surgeon for several rea-
sons. The clinical syndrome is uncommon, and,
therefore, even experienced surgeons may have only
a limited personal experience in the treatment of the
syndrome.1-5 Furthermore, the diagnosis is often dif-
ficult to establish with certainty in the clinical setting
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Purpose: The purpose of this study was to determine the safety and efficacy of the elec-
tive surgical treatment of symptomatic chronic mesenteric occlusive disease (SCMOD)
and to identify the factors that influence the results of this procedure.
Methods: From 1977 to 1997, 85 patients (mean age, 62 years) underwent elective sur-
gical treatment of SCMOD. The presenting symptoms were abdominal pain in 78
patients (92%) and weight loss in 74 patients (87%). The surgical procedures included
retrograde bypass grafting in 34 patients (40%), antegrade bypass grafting in 24 patients
(28%), transaortic endarterectomy in 19 patients (22%), local arterial endarterectomy
with patch angioplasty in six patients (7%), thrombectomy alone in one patient (1%), and
superior mesenteric artery reimplantation in one patient (1%). Thirty-five patients (41%)
underwent concomitant aortic replacement. All the involved mesenteric vessels were
revascularized in 21 patients (25%), whereas revascularization was incomplete for the
remaining 64 patients (75%). Late information was available for all 85 patients at a mean
interval of 4.8 years.
Results: There were seven early (<35 days) postoperative deaths (8%). The cumulative 5-
year survival rate was 64% (95% confidence interval [CI], 53% to 75%), and the 3-year
symptom-free survival rate was 81% (95% CI, 72% to 90%). Serious complications
occurred in 28 patients (33%). The results of univariate analysis identified advancing age
at operation (P < .001), cardiac disease (P = .03), hypertension (P = .03), and addition-
al occlusive disease (P = .05) as variables associated with mortality. Concomitant aortic
replacement (P = .037), renal disease (P = .011), advancing age (P = .035), and complete
revascularization (P = .032) were associated with postoperative morbidity including mor-
tality. Late recurrent mesenteric occlusive disease was seen in 21 patients (16 symptomatic
and five asymptomatic). Nine patients (43%) died, and 8 patients (38%) required subse-
quent surgical or endovascular procedures to treat their recurrent lesions. The 3-year sur-
vival rate from recurrent mesenteric occlusive disease was 76% (95% CI, 66% to 86%).
Conclusion: We conclude that the elective surgical treatment of SCMOD may be per-
formed with reasonable early and late mortality rates and that most of the patients
remain free from recurrent symptoms of mesenteric ischemia. Advancing age, cardiac
disease, hypertension, and additional occlusive disease significantly influenced the over-
all mortality rates, and concomitant aortic replacement, renal disease, and complete
revascularization were significantly associated with postoperative morbidity rates.
Surveillance and appropriate correction of recurrent disease appear to be necessary for
optimal long-term results. (J Vasc Surg 1999;29:821-32.)
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because the symptoms may be nonspecific until late
in the course of the disease. Patients with SCMOD
often are elderly and malnourished and have comor-
bid conditions that increase the risk of surgical pro-
cedures that frequently are technically demanding.
Finally, many aspects of the management remain con-
troversial, such as the method of revascularization,
the number and priority of vessels that necessitate
reconstruction, the configuration of the bypass
grafts, and the choice of the graft material itself.4,6-9
Consequently, this study was undertaken to deter-
mine the postoperative mortality and morbidity rates
associated with the surgical management of SCMOD
at our own center, to document the late survival and
recurrence rates in these patients, and to identify clin-
ical factors that may influence the ultimate outcome.
PATIENTS AND METHODS
We collected retrospective data from the hospital
records of 85 consecutive patients who underwent
surgical treatment of symptomatic chronic mesenteric
ischemia at the Cleveland Clinic from September
1977 to June 1997. Long-term information was
obtained during subsequent office visits or with tele-
phone contact with the patients, their immediate fam-
ilies, or their local physicians. The inclusion criteria
were intentionally strict. Only patients with indis-
putable SCMOD, on the basis of a history of post-
prandial abdominal pain or otherwise unexplained
weight loss in the presence of severe mesenteric occlu-
sive disease documented with angiography, were con-
sidered for analysis. Patients who were asymptomatic
or those patients with acute mesenteric ischemia,
splanchnic aneurysms, nonocclusive arterial disease,
median arcuate ligament compression syndrome, or
mesenteric venous thrombosis were specifically
excluded. Among the patients with coexisting aortic
aneurysms, only those who had typical symptoms of
chronic mesenteric ischemia and angiographic find-
ings consistent with these symptoms were included.
Patients whose symptoms may have been attributed
to the aneurysm itself or to some other gastrointesti-
nal disease also were excluded from this series. The
end points for survival analysis were defined as death
or recent follow-up examination within 6 months of
the study closure. Other outcome variables included
the recurrence of mesenteric ischemic symptoms or
the objective evidence of restenosis or reocclusion,
irrespective of symptoms, which occurred either dur-
ing surgery or during late surveillance. Follow-up
examination was complete for all 85 patients at a
median interval of 3.1 years (mean, 4.8 years;
interquartile range, 1.6 to 6.7 years).
The study group consisted of 25 men and 60
women, with a mean age of 62 years (median, 65
years; range, 27 to 89 years) at the time of the initial
operations. The associated risk factors, as defined by
the suggested reporting standards,10 are summa-
rized in Table I. Of note, 75 patients (88%) were
smokers, whereas only 6% had diabetes. Seventy-two
patients (85%) had coexistent arterial disease involv-
ing vascular beds other than the mesenteric circula-
tion, such as the cerebrovascular, renal, or lower
extremity arteries. Fifty-seven patients (67%) had
involvement of two or more additional arterial beds.
Four patients (5%) had previously undergone
mesenteric revascularization at another hospital
before they were seen at the Cleveland Clinic with
recurrent symptoms of chronic mesenteric ischemia.
All 85 patients were symptomatic with either
postprandial abdominal pain or weight loss (mean,
32 lbs; median, 30 lbs; range, 3 to 100 lbs), and
some had additional symptoms that are indicated in
Table II. Forty-one patients (48%) were first seen
with an abdominal bruit, 16 (19%) with gastroin-
testinal bleeding, and one each (1%) with fever or
tachycardia. Thirty-six patients (42%) had abdomi-
nal tenderness, but none had evidence of peritoneal
irritation. Laboratory studies, which included com-
plete blood counts, electrolyte determinations, renal
and liver function tests, coagulation studies, and
arterial blood gases, rarely had abnormal results and
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Table I. Surgical risk factors
Risk factors No. of patients (n = 85)
Smoking 75 (88%)
Hypertension 50 (59%)
Coronary artery disease 28 (33%)
Chronic obstructive pulmonary disease 27 (32%)
Congestive heart failure 24 (28%)
Renal disease 14 (16%)
Hyperlipidemia 10 (12%)
Diabetis mellitus 5 (6%)
Table II. Preoperative symptoms
Presenting symptoms No. of patients (n = 85)
Abdominal pain 78 (92%)
Weight loss 74 (87%)
Diarrhea 37 (44%)
Anorexia 28 (33%)
Food fear 15 (18%)
Constipation 14 (17%)
Pain or weight loss 85 (100%)
were not helpful. These patients usually had under-
gone extensive investigation before the diagnosis of
SCMOD, and 71 had undergone an average of 2.8
nonvascular diagnostic studies before surgical inter-
vention, which led to a mean delay of 11.5 months
(range, 1 day to 5.3 years) from the onset of symp-
toms to the time of the diagnosis.
All the patients underwent angiography before
surgical treatment. Not all of the original angiograms
were available for review because some of these stud-
ies were done at referring hospitals and the results
were inaccessible. However, occlusive disease was
considered to be clinically important if the preopera-
tive angiogram results showed occlusion or stenosis
‡ 50% or if the stenosis was reported as severe by the
radiologist or the attending physician. Those vessels
that were reported as mildly or moderately stenotic
were not considered in the analysis. The distribution
of diseased mesenteric vessels that were reported on
angiography is shown in Table III. All 85 patients had
clinically important occlusive disease that involved the
superior mesenteric artery (SMA), and there was sig-
nificant involvement of the celiac axis in 71 patients
(84%) and of the inferior mesenteric artery in 59
patients (69%). The extent and frequency of hypogas-
tric artery involvement are probably underestimated
because many of the records failed to describe the
angiographic appearance of these vessels. Four
patients (5%) had involvement of the SMA only,
whereas 32 patients (38%) had two-vessel involve-
ment and 49 others (58%) had stenosis or occlusion
of all three mesenteric vessels. Associated aortic
aneurysms were found in 18 patients (21%), and 49
patients (58%) had concomitant aortic occlusive dis-
ease. Four patients had small aneurysms that did not
warrant repair at the time of mesenteric revasculariza-
tion. Nevertheless, 35 patients did require concurrent
aortic grafts (eight interposition and 27 bifurcated)
for aneurysmal or occlusive disease. Eight patients
(9%) also underwent simultaneous surgical correction
of 10 renal artery lesions with either renal artery
bypass grafting (n = 7) or reimplantation (n = 3).
During the 20 years in which this series was col-
lected, six methods of surgical revascularization were
used (Table IV). The retrograde bypass grafts origi-
nated from the infrarenal aorta, an aortic graft, or the
common iliac artery. Transaortic endarterectomy
usually was performed through a trapdoor aortotomy
or, in the presence of a suprarenal aortic aneurysm,
through the opened aneurysm itself. All the transar-
terial endarterectomies were closed with autogenous
vein patch angioplasties. A single patient underwent
elective SMA thrombectomy and vein patch angio-
plasty after a 6-week history of postprandial abdomi-
nal pain. Another patient underwent reimplantation
of the SMA into the infrarenal aorta and subsequent-
ly required a retrograde aorta-to-SMA Dacron graft
for recurrent mesenteric ischemic symptoms 19
months later. An autogenous saphenous vein was
used for five of the 58 bypass grafting procedures
(9%), whereas synthetic grafts (51 Dacron and two
polytetrafluoroethylene) were used for the remaining
53 bypass grafting procedures (91%).
Complete revascularization was defined as the
repair of all the involved mesenteric vessels and was
performed in 21 patients (25%). Most of the 64
patients (75%) underwent revascularization that, to
some extent, was incomplete.
The median length of hospitalization (22 days)
during the first 15 years of the study decreased to 14
days during the last 5 years. However, the change in
the length of postoperative hospitalization, defined as
the interval from the date of operation to the date of
hospital discharge, was not as dramatic (14 days vs
12 days; P = .03, with Wilcoxin rank sum test).
The overall survival interval was the time from the
date of surgery to the date of last follow-up examina-
tion or death from any cause. The symptom-free inter-
val was defined as the time from the date of surgery
to the last follow-up examination or the first recur-
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Table III. Angiographic distribution of mesenteric
occlusive disease
Involved arteries No. of patients (n = 85)
SMA 85 (100%)
Celiac 71 (84%)
IMA 59 (69%)
Right hypogastric 14 (16%)
Left hypogastric 10 (12%)
SMA only 4 (5%)
Celiac and SMA only 22 (26%)
SMA and IMA only 10 (12%)
Celiac, SMA, and IMA 49 (58%)
SMA, Superior mesenteric artery; IMA, inferior mesenteric artery.
Table IV. Methods of arterial reconstruction
Primary procedures No. of patients (n = 85)
Retrograde bypass grafting 34 (40%)
Antegrade bypass grafting 24 (28%)
Transaortic endarterectomy 19 (22%)
Transarterial endarterectomy 6 (7%)
Arterial thrombectomy 1 (1%)
Arterial reimplantation 1 (1%)
rence of postoperative mesenteric ischemic symptoms.
The objective recurrence–free interval is from the date
of surgery to either the last follow-up examination or
the first discovery of restenosis or occlusion of any
revascularized vessel as determined with an objective
evaluation (angiography, ultrasound scanning, or sur-
gical exploration), irrespective of symptoms. Finally,
the overall freedom from mesenteric ischemia interval
was defined as freedom from mesenteric ischemia at
last follow-up examination or death.
The Kaplan-Meier survival curves were calculat-
ed for overall survival rate, symptom-free survival
rate, objective recurrence–free survival rate, and
overall survival from mesenteric ischemia rate. The
survival rates were determined for the entire cohort
of 85 patients. The objective recurrence–free sur-
vival rate differed from the symptom-free survival
rate by five patients who were asymptomatic at the
time of their objective recurrence. The overall sur-
vival rate from mesenteric ischemia includes some
patients who underwent secondary procedures to
correct recurrent symptoms.
Statistical analysis. The association between the
baseline variables and the early (30-day) morbidity
and mortality rates was assessed with Fisher exact
test, c 2 test, or logistic regression. The Kaplan-Meier
estimates of the survival rate distribution11 and the
95% confidence intervals (CIs) at various time points
were generated for overall survival rate, symptom-
free survival rate, freedom from objective recurrence
rate, and ultimate freedom from mesenteric ischemia
rate. The univariate association of baseline variables
with each survival outcome was assessed with the
Cox proportional hazards model. The risk ratios and
the 95% CIs indicate the risk of the outcome at any
point in time in the risk group as compared with the
reference group. For continuous variables, the ratio
indicates the estimated increase in risk for a specified
increment in the variable. Multivariable models were
attempted where appropriate for each outcome. A P
value of .05 was considered significant for each
hypothesis. SAS statistical software (SAS Institute,
Inc, Cary, NC) was used for all analyses.12
RESULTS
Early mortality and morbidity rates. Of all
the 85 mesenteric revascularization procedures,
there were five early (<30 days) postoperative deaths
(6%). These were caused by early graft occlusions
that resulted in bowel ischemia and multisystem
organ failure in three patients, by myocardial infarc-
tion in one patient, and by intraoperative cardiac
arrest before the correction of mesenteric ischemia
was accomplished in one other patient. Two other
deaths occurred at 32 days and 33 days during the
same hospitalization period as the index operation.
One of these patients had pneumonia, and the other
patient had respiratory failure and pneumonia devel-
op after a stroke. These two patients eventually died
of multi-system organ failure. Both of these addi-
tional deaths were judged to be causally related to
the preceding vascular operations, yielding an over-
all perioperative (<35 days) mortality rate of 8% (7
of 85) for the entire series. All 78 patients who sur-
vived the initial operation and were discharged from
the hospital had relief of their symptoms.
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Fig 1. Cumulative overall survival rates (Kaplan-Meier method), with 95% confidence intervals.
Thirty-eight patients (45%), including the seven
patients who died in the early postoperative period,
were noted to have one or more postoperative com-
plications. A total of 97 complications occurred in
the 38 patients, with some patients having more
than one complication (Table V). Of the 32 gas-
trointestinal complications, only five clearly were
related to the adequacy of perfusion. Four involved
bowel infarction or ischemia, and hepatic infarction
developed in another patient. An additional patient
had acalculous cholecystitis develop, and another
had a bleeding gastric ulcer. Ten of the 38 patients
who had any postoperative complications had pro-
longed ileus that required temporary parenteral
nutrition as their only complication. If this relatively
minor complication is excluded from the analysis,
serious complications occurred in 28 of the 85
patients (33%) in the entire series.
Late survival and freedom from recurrence
rates. Including the seven early postoperative
deaths, a total of 41 patients had died by the time of
the study closure. The overall survival rate for the
entire series was 64% at 5 years (95% CI, 53% to
75%) and 36% at 10 years (95% CI, 22% to 51%; Fig
1). Cardiac complications or cancers each were
responsible for eight of the 34 late deaths (23%),
strokes for three (9%), renal failure for two (6%), and
miscellaneous events for six (18%).
At late follow-up examination, 44 patients were
still alive and none had symptoms of mesenteric
ischemia. Seven of the 34 late deaths (21%), howev-
er, were caused by recurrent mesenteric ischemia
that could not be corrected. Consequently, the
cumulative overall 3-year survival rate from mesen-
teric ischemia at last follow-up examination was 87%
(95% CI, 79% to 94%) for all 85 patients (Fig 2).
When the 16 patients in this series who eventu-
ally returned with recurrent symptomatic mesenteric
ischemia after mesenteric revascularization originally
performed at the Cleveland Clinic are considered,
the mortality rate for acute presentation of recurrent
symptoms was 73% (8 of 11) as compared with 20%
(1 of 5) for those patients whose recurrent symp-
toms developed gradually. Another four patients in
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Fig 2. Cumulative survival from mesenteric ischemia rates at last follow-up examination
(Kaplan-Meier method), with 95% confidence intervals.
Table V. Early postoperative complications
Complications No. of patients
Gastrointestinal 32
Prolonged ileus 25
Bowel infarction/ischemia 4
Gastric ulcer hemmorrhage 1
Hepatic infarction 1
Acalculous cholecystitis 1
Pulmonary 25
Cardiac 13
Sepsis 8
Renal 7
Miscellaneous 12
Hemorrhage 4
Venous thrombosis 3
Wound complications 3
Leg ischemia 1
Stroke 1
Total 97
Deaths 7
Patients with more than one complication 38
the series had undergone reoperations without mor-
tality at the Cleveland Clinic for the gradual recur-
rence of chronic mesenteric ischemic symptoms after
initial mesenteric revascularization performed at
another institution. Consequently, a total of nine
patients in this series underwent operation for recur-
rent chronic mesenteric ischemia at the Cleveland
Clinic with one perioperative death (11%).
Fifty-four patients (64%) had postoperative paten-
cy of their mesenteric revascularizations as evaluated
with objective measures, and 23 of these patients
underwent more than one type of objective determi-
nation. Thirty-two patients underwent duplex ultra-
sound scan examinations, 38 patients underwent
either intravenous or intra-arterial angiography, and 11
others underwent direct surgical exploration for recur-
rent symptoms. For these patients, the calculation of
survival rate to first recurrence preferentially used the
interval to the objective evaluation that first showed
the recurrence. Among the remaining 31 patients who
never underwent objective postoperative evaluations,
21 were alive without mesenteric ischemic symptoms
at late follow-up examination and 10 others had died
of causes that were determined to be unrelated to
mesenteric ischemia. Consequently, although the
objective recurrence–free survival rate may approxi-
mate the primary patency rate of the mesenteric revas-
cularization procedures, it probably underestimates
the true anatomic recurrence rate because 31 patients
never underwent objective evaluation.
At late follow-up examination, 18 patients had
objective evidence of restenosis or occlusion of their
revascularized mesenteric vessels. When one considers
the three early graft failures that caused early postop-
erative deaths in all three patients, there were 21
patients with demonstrated recurrent mesenteric
occlusive disease. For this analysis, a patient was con-
sidered to have a recurrence if any one of the recon-
structed vessels was stenotic or occluded, as shown
with objective testing, irrespective of mesenteric
ischemic symptoms. The method of salvage and the
outcome for each of these patients are summarized in
the following manner: three patients died in the early
postoperative period, three patients underwent a sal-
vage procedure that also failed, and three others were
not able to be reconstructed at the time of reopera-
tion. Seven patients who were symptomatic under-
went salvage with either a reoperation or a catheter-
based intervention. Of the five patients with asympto-
matic recurrences, one reconstruction was occluded
and the remaining four patients had developed
restenoses. One patient with asymptomatic restenosis
underwent an endovascular procedure to reopen the
SMA, and the other four patients underwent conser-
vative treatment. All five patients remained asympto-
matic at late follow-up examination. The estimated 3-
year objective recurrence-free survival rate was 76%
(95% CI, 66% to 86%) for all patients (Fig 3). The
estimated 3-year symptom-free survival rate for all
patients was 81% (95% CI, 72% to 90%; Fig 4).
Univariate analyses. A number of factors were
analyzed to assess their association with early postop-
erative death (<35 days). The following factors were
not found to be significantly associated with early
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Fig 3. Cumulative freedom from objective recurrence rates (Kaplan-Meier method), with 95%
confidence intervals.
postoperative mortality rates: gender; the number of
vascular beds involved; the year of surgery; the extent
of revascularization; the method and configuration of
reconstruction; the graft material used; the necessity
for concomitant aortic or renal surgery; and the pres-
ence of the risk factors, including diabetes mellitus,
smoking, hypertension, hyperlipidemia, coronary
artery disease, pulmonary disease, and renal dysfunc-
tion. However, with only seven deaths, there was lit-
tle statistical power to detect the important associa-
tions that may have existed. The only factor that was
significantly associated with early postoperative mor-
tality was the conduit type used in those patients who
underwent bypass grafting procedures. Two of five
patients (40%) who underwent autogenous saphe-
nous vein bypass grafting procedures died during
surgery, and only two of 53 patients (4%) who
received synthetic grafts died (P = .03).
Univariate analysis results revealed that advancing
age at the time of operation (P < .001), a preopera-
tive history of hypertension (P = .03), preexisting
cardiac disease (P = .03), and the presence of disease
in other vascular beds (P = .05) were significantly
associated with overall survival rates (Table VI).
No factors were significantly associated with
postoperative morbidity or death and morbidity
rates considered together. However, if prolonged
ileus is considered a minor complication, only 28 of
85 patients (33%) had major complications.
Concomitant aortic replacement (P = .037), pres-
ence of preoperative functional renal disease (P =
.011), and complete revascularization (P = .032)
were significantly associated with major postopera-
tive morbidity or death rates considered together.
Univariate analysis results revealed the graft material
used for a bypass to be the only variable significant-
ly associated with symptom-free survival rates (P =
.001), recurrence-free survival rates (P < .001), and
overall freedom from mesenteric ischemia rates (P =
.03). However, the small number of vein grafts (n =
5) makes these results unreliable (Table VII).
DISCUSSION
Mesenteric ischemia is a relatively rare clinical syn-
drome. Consequently, the guidelines for treatment
are few, which has led to controversy regarding opti-
mal management. In some reports, the distinction
between patients with acute and chronic mesenteric
ischemia is unclear, and, in some patients with chron-
ic symptoms, conditions can deteriorate rapidly,
which leads to acute presentation.2,3,5-7,9,13-21 Other
reports have included patients who had atypical symp-
toms or who were asymptomatic.2,5,7,13,14,18,22
To clarify the results of management, the inclu-
sion criteria for this study were intentionally strict,
limiting consideration to patients who had well-
defined symptoms, appropriate arterial occlusive dis-
ease, no other clear explanation for their symptoms,
and relief of their symptoms after surgery. The
female predominance and the median age of 65
years for our patients are consistent with other
reports.9,14 Seventy-five of the 85 patients (88%) in
our series were smokers, and only 6% (5 of 85) had
diabetes. These findings were also reported by other
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Fig 4. Cumulative freedom from recurrent symptoms rates (Kaplan-Meier method), with 95%
confidence intervals.
investigators.2-5,7,16,19-21,23,24 The presentation of
our patients was similar to that of patients in other
reports of chronic mesenteric ischemia.2,4,9,23
The mean interval from the onset of symptoms
to the time of diagnosis was nearly 1 year, and, dur-
ing this time, our patients underwent a mean of 2.8
diagnostic studies, excluding angiography or surgical
exploration, to evaluate their gastrointestinal tracts.
Chronic mesenteric arterial insufficiency has been
proposed to be a cause of recurrent refractory gastric
or duodenal ulceration, and some of our patients ini-
tially underwent pharmacologic treatment for endo-
scopic findings of gastric or duodenal inflammation
or ulceration. A few other patients also underwent
cholecystectomy for presumed biliary tract disease.
Noninvasive duplex ultrasound scan evaluation of
the mesenteric circulation before and after a stan-
dardized meal has been proposed as a stress test and
may prove to be a useful diagnostic adjunct.25
Among the patients in this series, coexistent ath-
erosclerotic occlusive disease was often found in other
locations. Consequently, patients who show evidence
of diffuse arterial occlusive disease with evaluation for
abdominal pain or unexplained weight loss should
undergo early ultrasound scanning or angiography to
rule out mesenteric ischemia. Conversely, patients
with documented chronic mesenteric ischemia
require clinical evaluation of their coronary, carotid,
and lower extremity circulations as part of their pre-
operative evaluations.
Although some authors have described patients
with chronic mesenteric ischemia in the pres-
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Table VI. Cox proportional hazards regression model results for association with recurrent symptoms of
mesenteric ischemia and survival
Association with recurrent symptoms Association with survival
Variable (reference group) Risk ratio (95% CI) P value* Risk ratio (95% CI) P value*
Gender (male) 1.43 (0.46 - 4.45) .53 1.45 (0.73 - 2.91) .29
Diabetes mellitus 1.33 (0.18 - 10.12) .78 1.80 (0.55 - 5.87) .33
Hypertension 0.72 (0.27 - 1.94) .52 2.13 (1.09 - 4.18) .03†
Smoking 0.80 (0.18 - 3.53) .76 0.60 (0.23 - 1.57) .3
COPD 1.07 (0.37 - 3.09) .9 1.64 (0.87 - 3.09) .12
CAD 1.06 (0.37 - 3.05) .92 1.99 (1.07 - 3.72) .03†
Hyperlipidemia 0.53 (0.07 - 4.01) .54 0.27 (0.04 - 1.97) .2
Renal disease NA .08 1.94 (0.86 - 4.38) .11
Surgery date (1990 to 1997) 1.52 (0.54 - 4.28) .42 1.54 (0.73 - 3.23) .25
Surgery type
Antegrade (retrograde) 1.70 (0.54 - 5.37) .36 1.09 (0.50 - 2.36) .83
Bypass grafting (endarterectomy) 1.69 (0.48 - 6.02) .41 1.76 (0.77 - 4.04) .18
Graft material (vein) 0.11 (0.03 - 0.46) <.001† 0.22 (0.04 - 1.08) .06
Aortic repair 0.57 (0.20 - 1.65) .3 1.06 (0.57 - 1.97) .84
Renal revascularization NA .19 1.23 (0.43 - 3.47) .7
Complete revascularization (incomplete) 0.20 (0.03 - 1.53) .12 0.61 (0.26 - 1.47) .27
Vascular beds (x + 1 vs x) 0.80 (0.57 - 1.12) .2 1.16 (0.94 - 1.43) .16
Vascular beds >1 (0 to 1 bed) 1.14 (0.39 - 3.29) .81 2.07 (1.00 - 4.29) .05†
Age (for 10 year difference) 0.70 (0.44 - 1.11) .13 2.0 (1.4 - 2.9) <.001†
COPD, Chronic obstructive pulmonary disease; CAD, coronary artery disease; NA, not calculable.
*P value from Cox proportional hazards regression model.
†P < .05 significant
Table VII. Association of graft material used for bypass with recurrence of symptoms, objective recur-
rence, and survival from mesenteric ischemia
Bypass graft conduit type
Vein (n = 5) Synthetic (n = 53) Risk ratio (95% CI)
Freedom from Events Events Vein vs synthetic (reference) P value*
Recurrent symptoms 3 (60%) 9 (17%) 9.1 (2.2 - 33) 0.001
Objective recurrence 4 (80%) 10 (19%) 17 (4.2 - 50) <.0001
Mesenteric ischemia 2 (40%) 7 (13%) 6.7 (1.2 - 33) .03
*P value from Cox proportional hazards model.
ence of only single-vessel disease (usually 
the SMA3-5,7,9,13,14,17-19,21-23,26 or the celiac
artery),26 it is generally agreed that evidence of
severe occlusive disease that involves at least two
of the three mesenteric vessels is necessary to 
support the diagnosis of chronic mesenteric
ischemia.25 Although all 85 patients in our series
had angiographic involvement of the SMA, most
of our patients (96%) had involvement of two or
more vessels and only four patients had occlusive
disease that was confined to the SMA alone. These
four patients had classic symptoms of chronic
mesenteric ischemia that were relieved with revas-
cularization. The role of the hypogastric circula-
tion is poorly defined and probably underestimat-
ed with our data. An evaluation of these vessels is
important because they are a source of pelvic col-
lateral circulation.
During the two decades of the study, a variety of
techniques was used to revascularize the mesenteric
circulation. The choice of procedure often was influ-
enced by the angiographic pattern of occlusive dis-
ease, a history of extensive abdominal surgery, and
surgeon preference. Saphenous vein was used in five
patients, presumably to avoid synthetic graft materi-
al during the original procedure. Most often, in 34
of 58 bypass grafting procedures (59%), retrograde
prosthetic bypass grafting to the SMA was per-
formed alone or in conjunction with aortic recon-
struction and had the advantage of not necessitating
dissection or cross clamping of the supra celiac aorta,
a preference advocated by others.27 The major dis-
advantage of this approach is that care must be taken
to place the graft in a near-vertical orientation from
its origin to its termination to minimize the tenden-
cy for kinking when the viscera are returned to their
normal anatomic position. Antegrade bypass graft-
ing avoids this problem, and transaortic endarterec-
tomy is useful when the occlusive disease involves
the aorta and is limited to the proximal mesenteric
artery. We did not find significant differences in early
or late mortality or morbidity rates among patients
in our series who underwent either bypass grafting
procedures (retrograde or antegrade) or endarterec-
tomies. Although there are strong proponents for
antegrade bypass grafting2,4,9,19,23,26,28,29 and for
retrograde orientation,3,27,30,31 no statistical superi-
ority has yet been shown by other investigators
either. Similarly, although some authors prefer syn-
thetic graft material6,26,32 and others advocate auto-
genous vein grafts,8,20 no clear superiority has been
shown. Although we found better symptom-free
survival rates, recurrence-free survival rates, and
overall survival from mesenteric ischemia rates when
synthetic grafts were compared with vein grafts, the
data must be interpreted with caution because only
five vein grafts were used in contrast to 53 synthetic
grafts. More importantly, it is probable that selection
bias accounts for some of these results. Vein grafts
are more likely be used in the treatment of critically
ill patients whose bowel viability is in question. The
vascular surgeon should be prepared to use all the
available techniques and to tailor the operative strat-
egy to the specific needs of the individual patient.
Although concomitant renal revascularization did
not adversely affect long-term outcome, concomitant
aortic replacement was associated with an increased
postoperative complication rate, which is a finding
reported by others.8,9 Our current approach is to use
aortic replacement only when clearly necessary.
Controversy also continues regarding the number
of involved mesenteric arteries that should be recon-
structed to ensure adequate revascularization. Some
authors advocate complete revascularization,8,9 and
others believe that only one vessel should be treated.4
We observed that all patients who ultimately died
because of mesenteric ischemia had undergone incom-
plete revascularization. Furthermore, more of those
who underwent incomplete revascularization had
recurrent symptoms of mesenteric ischemia and had a
lower 5-year symptom-free survival rate. The benefits
of complete revascularization, however, were obtained
at the expense of nearly twice the perioperative com-
plication rate. Nevertheless, because of the small num-
ber of patients, these results are not statistically signif-
icant. Conceding these uncertainties, we currently
attempt to reconstruct as many involved mesenteric
vessels, including the hypogastric arteries, as is feasible.
The perioperative mortality rate (8%) for our series
was conservatively determined and compared favor-
ably with the combined data from 27 reports, which
encompass 854 patients who underwent treatment for
chronic mesenteric ischemia, with perioperative mor-
tality rates ranging from 0 to 17%.2-9,13-24,26,27,30,32-35
In these reports, 38% of the early perioperative deaths
were caused by graft failure, a finding nearly identical
to our own experience (43%). These observations
emphasize the unforgiving nature of mesenteric revas-
cularization and the necessity for early revision as soon
as technical problems are recognized.
Complication rates for patients who have under-
gone mesenteric reconstruction for chronic mesen-
teric occlusive disease are poorly documented.23,26
Reported complication rates range from 19% to
54%,2,4,5,9,20 and, in our own study, 33% of patients
had major complications, some of which were fatal.
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We determined that the requirement for concomi-
tant aortic repair, complete revascularization, and
the presence of preexisting renal dysfunction were
three variables that were significantly associated with
the development of postoperative complications.
The first two are likely related to the magnitude and
duration of the operation. The presence of preexist-
ing renal dysfunction has been associated with post-
operative morbidity after aortic aneurysm repair,36
and its effect should be anticipated, especially if
suprarenal aortic cross clamping is necessary.
The cumulative 5-year survival and 5-year symp-
tom-free survival rates for patients who undergo surgi-
cal treatment of chronic mesenteric occlusive disease
range from 62% to 88% and 70% to 88%, respectively,
and compare favorably with those rates observed for all
85 patients in this series (64% and 74%, respective-
ly).2,4,6,7,9,13,18,23,30 We determined that occlusive dis-
ease in two or more additional vascular beds, the pres-
ence of preoperative hypertension, and cardiac disease
were variables that were significantly associated with
mortality. This observation probably reflects the pres-
ence of widespread atherosclerotic disease already
established at the time of the mesenteric reconstruc-
tion. The only variable found to be significantly asso-
ciated with symptom-free survival, however, was the
choice of graft material for the bypass. Patients who
had autogenous vein grafts had worse long-term relief
of symptomatic mesenteric ischemia than those who
underwent treatment with synthetic grafts. This obser-
vation may reflect patient selection or the small num-
ber of vein grafts used, or it may reflect as yet unde-
termined properties of the vein graft itself and should
be interpreted with caution. However, synthetic grafts
may have an advantage when their use is feasible.
Two additional survival rate analyses were per-
formed in an attempt to quantify the results of
patients in whom a restenosis of the mesenteric recon-
struction developed but who remained asymptomatic
(n = 5) and to describe the late outcome of the sub-
set of patients who required any reintervention for
recurrent symptoms. The 3-year recurrence-free sur-
vival rate of 76% (Fig 3) was less than the symptom-
free survival rate of 81% (Fig 4) because the former
considered five more patients as recurrent than did
the latter. Furthermore, the calculated recurrence-free
rate of 64% in 54 patients who had undergone post-
operative objective testing for patency probably over-
estimates the true anatomic recurrence-free rate
because all of the 31 untested patients remained
asymptomatic. Nevertheless, we currently recom-
mend surveillance with annual duplex ultrasound scan
studies of the mesenteric vessels for patients who are
asymptomatic after surgery and with mesenteric
angiography for those patients with recurrent mesen-
teric ischemic symptoms or those with recurrent
mesenteric stenoses confirmed with duplex ultra-
sound scanning. The overall survival rate from mesen-
teric ischemia was calculated for those patients in
whom recurrence of mesenteric occlusive disease
developed but who underwent treatment with either
reoperation or endovascular intervention. The 3-year
overall survival rate from mesenteric ischemia was 87%
because seven of the 16 patients who had sympto-
matic recurrences underwent salvage with reinterven-
tion (Fig 2). Consequently, the surgical treatment of
SCMOD is associated with an 8% perioperative mor-
tality rate and an 81% chance of remaining symptom-
free at 3 years after surgery (Fig 4). If symptomatic
mesenteric arterial stenosis recurs and is treated with
reintervention, patients have an 87% chance of surviv-
ing from mesenteric ischemia for 3 years after the
original operation (Fig 2). Reintervention seems jus-
tified for patients with symptomatic recurrences but,
because of limited experience and lack of data, should
be individualized for patients who are asymptomatic
and may be justified for three-vessel disease.37
The outcome for patients with recurrent symp-
toms of mesenteric ischemia appears to be influenced
by their clinical presentation. In our own series, eight
of 11 patients (73%) who had acute symptoms died,
whereas only one of nine patients (11%) with chron-
ic recurrent symptoms did not survive. These results
are comparable with those of Schneider et al38 (86%
vs 9%, respectively).38 Consequently, it appears that
reintervention for recurrent chronic mesenteric
ischemia may be performed with acceptable morbid-
ity and mortality rates, especially if acute presentation
can be avoided.
We used endovascular intervention in only four of
our patients with recurrent mesenteric occlusive dis-
ease, with initial successful revascularization accom-
plished in three. Because reports concerning the use
of percutaneous angioplasty and stenting for mesen-
teric occlusive disease are currently anecdotal, it is not
possible to predict with certainty its role in the treat-
ment of chronic mesenteric ischemia.21 The issue of
durability is clearly a concern and will necessitate fur-
ther careful study. As experience with endovascular
approaches increases, percutaneous angioplasty and
stenting may become a reasonable option for some
patients, especially those who require reoperations or
those with hostile abdomens.
We conclude that the elective surgical treatment
of SCMOD may be performed with reasonable early
and late mortality rates and that most of these
patients remain free from recurrent symptoms of
mesenteric ischemia. Advancing age, cardiac disease,
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hypertension, and additional occlusive disease signif-
icantly influenced overall mortality rates, and con-
comitant aortic replacement, renal disease, and com-
plete revascularization were significantly associated
with postoperative morbidity rates. Surveillance and
appropriate correction of recurrent disease appear to
be necessary to obtain optimal long-term results.
We thank Becky Roberts for her help in the collection
of data.
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Dr Peter Gloviczki (Rochester, Minn). I enjoyed your
paper, and I think it is important to bring up this topic
again from time to time for discussion. In our last review
that was published by Drs McAfee and Cherry, we had
many similar findings. Our mortality rate in 58 patients
was similar. It was 10%, and it may be because some of the
patients we had either had more acute symptoms or were
higher surgical risks. Mortality and morbidity rates were
higher, as you also noted, among patients who required
concomitant aortic replacement. Similar to your group,
we also recommend revascularization of as many vessels as
possible but at least revascularization of the celiac and
superior mesenteric arteries. The long-term graft patency
rate in our series was 90% in those patients who under-
went complete revascularization. We specifically analyzed
the effectiveness of different types of graft material, but we
could not show a statistically significant difference.
Although we all favor antegrade revascularization from the
supraceliac aorta, we had satisfactory results with retro-
grade bypass grafting and transaortic endarterectomy as
well, and we could not confirm a difference. In your con-
clusion, you suggest complete revascularization. At the
same time, however, you also tell us that major postoper-
ative complications were most frequent in this group of
patients. Could you tell under which situation you would
be satisfied with revascularization of the single vessel and
not jeopardize the patient with the increased morbidity of
attempts at complete repair?
Dr Patrick J. O’Hara. Dr Gloviczki, thank you for
your question regarding the optimal extent of mesenteric
revascularization. We are familiar with your extensive expe-
rience in this area at the Mayo Clinic. In the manuscript,
we acknowledged the existing controversy regarding the
number of involved mesenteric arteries that should be
reconstructed to ensure adequate revascularization. In our
own series, all patients who eventually died of mesenteric
ischemia had received incomplete revascularization. Also,
patients with incomplete revascularization had a lower 5-
year, symptom-free survival rate and more of these patients
experienced recurrent symptoms. However, because the
sample size was small, these results are not statistically sig-
nificant. Although the benefits of complete revasculariza-
tion, in our series, were obtained at the expense of nearly
twice the perioperative complication rate, most complica-
tions were not fatal. Consequently, we currently believe it
is reasonable to attempt to reconstruct as many involved
mesenteric vessels, including the hypogastric arteries, as it
is feasible, but the decision must clearly be individualized.
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